I think that the company is doing the prudent thing by keeping as much cash as possible at least until end points of p3 trials is clear and also until we have licensed out NNZ2591 as a whole platform ( less Acadia's 2 indications) if we haven't been taken over beforehand.
if licence deal or takeover not enacted we may have up to 10 different indications to take through trials and FDA approval , more than a billion dollars. What is even a $1 per share special dividend going to do to improve markets valuation of NEU? In current market probably just reduce our much undervalued price by a $1 or more.
NEU Price at posting:
$13.23 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)